Kornimate/medical-research-clean huggingface dataset:
effectiveness of nutritional supplementation in preventing malnutrition in children with infection in karamoja, uganda

Conditions: Child Malnutrition; Infant Morbidity

Summary: the purpose of this study is to determine whether 14 days nutritional supplementation with ready to use therapeutic food (rutf) or micronutrients alone to children having an infection will prevent malnutrition and reduce the frequency of morbidity.

similar to msf-nutcon 03 : nct01154803

Eligibility criteria:
inclusion criteria: * 6 to 59 months of age * not malnourished * diagnosis of malaria and/or diarrhoea and/or lrti * intending to remain in area for the duration of the 6 month follow-up * living within approximately 60 minutes walking distance from the clinic * informed consent from a guardian\* exclusion criteria: * child is exclusively breastfeeding * child is severely malnourished * presence of 'general danger signs' * presence of severe disease (including severe malaria, severe lrti, severe diarrhoea) * needing hospitalisation for any reason * known history of allergy to the nutritional supplementation * having a sibling enrolled in the study\*
collection of liver tissue for virologic studies

Conditions: Virus Disease

Summary: this study will examine liver tissue to investigate the role of viral infections in fulminant hepatitis, liver failure, and profound bone marrow failure. all patients who are undergoing liver biopsy or liver transplantation may participate in this study. for patients undergoing liver biopsy, a small piece of liver tissue will be taken from the sample collected during the scheduled biopsy. for patients undergoing liver transplantation, a small piece of tissue will be collected from the diseased liver that is to be removed.

our laboratory has a long-standing interest in viruses that affect the bone marrow. many such viruses also may cause hepatitis. one specific syndrome, post-hepatitis aplastic anemia, suggests that the same agent is responsible for both severe and sometimes fulminant hepatitis as well as profound bone marrow failure. in investigating the role of viruses in these diseases, we require small amounts of liver tissue for molecular studies. we request permission to obtain samples from patients undergoing 1) liver transplantation or 2) liver biopsy at the time of surgery for purpose of virus discovery, including obtaining control samples. for liver transplant samples, tissue will be obtained from the removed organ; in other surgical circumstances, small amounts of tissue will be obtained when the liver is biopsied for other medical indications. no additional risk to the patient should result from either procedure.

Eligibility criteria:
all patients undergoing open liver biopsy or the removal of liver for purposes of hepatic transplantation are eligible for participation. there are no exclusion criteria.

Keywords: fulminant hepatitis parvovirus hepatitis biopsy control liver biopsy
phase 1/2 sequentially staged safety study in healthy subjects and subjects with mild acne

Conditions: Acne

Summary: the purpose of this study is to determine the safety of photodynamic therapy (pdt) with lemuteporfin topical solution (lts) in healthy subjects and subjects with mild acne.

this is a sequentially staged (stage 1-4), proof of concept study assessing the safety of photodynamic therapy (pdt) and lemuteporfin topical solution (lts) in healthy subjects and subjects with mild acne. approximately 12 subjects will be enrolled in stage 1 in order to determine a maximum tolerated light dose following lts application. up to 90 subjects with mild acne will be enrolled in stage 2 in order to assess the safety of pdt following a single lts application. up to 50 subjects will be enrolled in stage 3 in order to assess the safety of pdt following repeat lts applications. up to 40 subjects will be enrolled into stage 4 to assess multiple treatments of lts-pdt.

Eligibility criteria:
inclusion criteria: * stage 1 only: healthy subjects * stage 1-4: male or female subjects age 18 years or older * stage 2: subjects with sebum excretion rate of 4 or higher on forehead * stage 2-4: subjects with at least 2 inflammatory acne lesions on the forehead * stage 3-4: subjects with sebum excretion rate of 5 or higher on forehead exclusion criteria: * poor skin condition on back (stage 1) or face (stage 2 \& 3) * severe facial acne, acne fluminans/conglobata, or nodulocystic acne * stage 2-4: previous use of diane-35 within 6 months of day 0, systemic acne treatment or systemic antibiotic treatment within 28 days of day 0, topical acne treatment to the face within 14days of day 0 or pdt to the face within 3 months of day 0 * stage 2-4: previous treatment of isotretinoin or other oral retinoids

Keywords: acne sebum gland disease
rtms and conventional physical therapy after stroke

Conditions: Stroke

Summary: given previous evidence that non invasive brain stimulation enhances the effects of conventional therapies, this randomized sham-controlled trial with 4-weeks follow-up aimed to determine if the repetitive transcranial magnetic stimulation (rtms)combined with conventional physical therapy (vrt) would be superior to physical therapy in improving upper limb function and quality of life with chronic stroke individuals.


Eligibility criteria:
inclusion criteria: * stroke onset ≥ 6 months; * muscle tone at the wrist with a modified ashworth scale (mas) score between 1+ and 3; * minimum age of 30 years old and maximum age of 75 years; * absence of cognitive impairment, as determined by the cut-off scores on the mini-mental state exam exclusion criteria: * history of seizure or cerebral aneurism; * antispasticity drugs within 6 months before enrollment; * previous surgery involving metallic implants; * unstable vital signs; * other neurological diseases * aphasia

Keywords: transcranial magnetic stimulation spasticity physiotherapy rehabilitation
technical development for pediatric cardiovascular mri

Conditions: Congenital Heart Disease; Cardiovascular Disease

Summary: this study will explore new ways of using magnetic resonance imaging (mri) to evaluate pediatric patients with cardiovascular disease,congenital heart disease in patients of all ages, fetuses undergoing clinically indicated mr imaging.

the purpose of this protocol is to allow development and testing of new mri techniques suitable for evaluating patients with cardiovascular disease, congenital heart disease, fetal cardiac structure, function, and physiology, and other fetal organ analysis. individuals referred to children's national medical center for a clinically indicated cardiac mri or cardiac catheterization by their primary referring cardiologist or obstetrician, and who are enrolled in this study may also undergo additional research imaging. since such technical development work often depends on preliminary studies in healthy volunteers, the protocol also recruits healthy subjects.

Eligibility criteria:
inclusion criteria: clinically indicated exams 1. patients who are undergoing a medically indicated mri scan or cardiac catheterization procedure 2. patients who are medically judged to have no contraindications to mri scan 3. age inclusion: infant to adult 4. written informed consent and assent, when applicable volunteers 1. written informed consent from any normal volunteer 8 years of age or older for a noncontrast, nonsedated cardiac mri 2. normal adult volunteer to undergo cardiac mri with contrast agent fetal exams 1. age inclusion:18 years and older 2. second or third trimester (greater than 13 weeks) exclusion criteria: 1. all patients who are medically judged to have contraindication(s) to mri scanning will be excluded. contraindications include implanted metal devices which are contraindicated for mri scanning: * central nervous system aneurysm clips; * implanted neural stimulator; * implanted cardiac pacemaker or defibrillator; * cochlear implant; * ocular foreign body (e.g. metal shavings); * implanted insulin pump; * metal shrapnel or bullet. 2. exclusion criteria for bicycle stress mri * myocardial infarction within 24 hours * active myocarditis * uncontrolled heart failure * severe left ventricular outflow tract obstruction 3. exclusion criteria for adult volunteers undergoing mri with administration of contrast agent: * 60 years of age or older * renal disease; glomerular filtration rate (egfr \< 30 ml/min/1.73 m2) will be determined by a simple blood test done at the bedside * use of diuretics * diagnosis of hypertension and diabetes 4. exclusion criteria for volunteers undergoing both contrast and non-contrast mri scans: * pregnant women: 1. women of childbearing potential will be required to have a screening urine pregnancy test 5. exclusion criteria for * pregnant woman for whom 15 additional minutes lying flat in the mr scanner would represent a risk (i.e. severe claustrophobia, congestive heart failure) * pregnant minor under the age of 18 * less than 13 weeks gestation
duration of im injection and pain intensity

Conditions: Pain Measurement

Summary: this study was a single-group crossover clinical trial, where each participant acted as their own control. the study aimed to describe the relationship between perceived pain and the duration of intramuscular injections

the study was a single-group crossover clinical trial, where each participant acted as their own control. the study sample included 50 patients aged 25 to 55 who met the inclusion criteria of signing an informed consent form and requiring administration of a specific antibiotic via intramuscular injection, as prescribed by physicians. two intramuscular injections into the right and left dorsal gluteal region (drg) were recorded for each participant. one was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. a day after, the same nurse gave the other injection in the opposite dgr, taking 40 seconds to administer. the five-second injections were considered the control group, while the 40 seconds injections were the intervention group. the order of interventions was randomized. the pain level was determined and recorded immediately after each injection. the study was conducted between september 2019 to november 2019 in the emergency unit of an educational hospital in istanbul. the data was collected using a demographic form, facial expressions scale, and visual comparison scale. statistical analysis was performed using the kolmogorov-smirnov test, mann-whitney u test, wilcoxon test, and spearman correlation analysis, with a significance level of p \< 0.05.

Eligibility criteria:
inclusion criteria: having a condition leads to prescribing clindamycin 600 mg/4 ml intramuscularly having no pain in the area of injection absence of any tissue damage history at the site of injection exclusion criteria: asking for withdrawal after signing the informed consent intensifying the disease/condition at the time of the second injection taking any analgesic medication before the application.

Keywords: intramusculer injection nurse pain intensity
btae-haic combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma

Conditions: Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Lenvatinib; Sintilimab

Summary: this study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (btae-haic) plus lenvatinib and camrelizumab for patients with infiltrative hepatocellular carcinoma.

blank-microsphere transcatheter arterial embolization (btae) and hepatic arterial infusion chemotherapy (haic) of oxaliplatin, 5-fluorouracil and leucovorin are effective and safe for hepatocellular carcinoma. lenvatinib is non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. sintilimab, a programmed cell death protein-1 (pd-1) inhibitor, is effective and safe in patients with unresectable hepatocellular carcinoma. no study has evaluated btae-haic plus lenvatinib and sintilimab. thus, the investigators carried out this prospective, single-arm study to find out it.

Eligibility criteria:
inclusion criteria: 1. diagnosis of infiltrative hcc. 2. infiltrative hcc was characterized as follows: nonencapsulated arterial phase hyperenhancement; tumor washout in the period of portal phase, and noncircular, ill-defined margin 3. age between 18 and 75 years; 4. the maximum tumor size ≥10 cm, and the total tumor size ≥15 cm; 5. infiltrative hcc, with pvtt type i or type ii or limited metastases (≤5). 6. child-pugh class a or b; 7. eastern cooperative group performance status (ecog) score of 0-2; 8. hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 32 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 9. prothrombin time ≤18s or international normalized ratio \< 1.7. 10. ability to understand the protocol and to agree to and sign a written informed consent document. exclusion criteria: 1. hcc with capsule; 2. extrahepatic metastasis \>5; 3. obstructive pvtt involving the main portal vein. 4. serious medical comorbidities. 5. evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy 6. known history of hiv 7. history of organ allograft 8. known or suspected allergy to the investigational agents or any agent given in association with this trial. 9. cardiac ventricular arrhythmias requiring anti-arrhythmic therapy 10. evidence of bleeding diathesis. 11. patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
evaluation of rectal infiltration depth and length in bowel involvement of deep infiltrative endometriosis (die) using intraoperative transrectal ultrasound (trus)

Conditions: Deep Infiltrating Endometriosis (DIE); Transrectal Ultrasound; Bowel Endometriosis; Bowel Resection

Summary: we aim to evaluate the success of intraoperative transrectal ultrasound in measuring the depth and extent of bowel involvement in patients preoperatively diagnosed with intestinal endometriosis using transvaginal ultrasound and mri, and who are planned for bowel resection

this is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (trus) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (die). the study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and mri, and scheduled for bowel resection. preoperative evaluations will include pelvic examination, imaging (tvus and mri), and pain assessment using a visual analog scale (vas). during surgery, trus will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative mri results. data will be analyzed using statistical methods, including sensitivity, specificity, and roc curve analysis, to determine the diagnostic performance of trus. the study will be conducted at istanbul başakşehir çam and sakura city hospital, with multidisciplinary contributions from gynecology, radiology, and general surgery teams.

Eligibility criteria:
inclusion criteria: * the study will include a minimum of 15 female patients aged 18-55 with bowel involvement due to deep infiltrative endometriosis, requiring bowel resection. exclusion criteria: patients with bowel endometriosis who does not require bowel resection, patients who have other bowel diseases, such as rectal tumors, crohn's disease, or ulcerative colitis, will be excluded. -

Keywords: deeply infiltrating endometriosis bowel endometriosis transrectal ultrasound bowel resection
safety of aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic urticaria (study p04446am1)(completed)

Conditions: Rhinitis; Urticaria

Summary: the objective of this non-interventional study is to evaluate the safety of aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic uticaria. the patients will receive 2.5 ml (1.25 mg) once daily.

pediatric patients aged 1-5 years

Eligibility criteria:
inclusion criteria: * patients with allergic rhinitis or chronic idiopathic urticaria * aged 1-5 years old * caregiver's consent to participate exclusion criteria: * healthy individuals * younger or older than the 1-5 year old age range
survivorship care planning in patients with colorectal or non-small cell lung cancer

Conditions: Stage I Colon Cancer; Stage I Rectal Cancer; Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Colon Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer

Summary: survivorship care planning may improve overall well-being and quality of life of colorectal and lung cancer survivors

primary objectives: i. to test the feasibility and acceptability of an advanced practice nurse (apn) driven survivorship care planning (scp) intervention for colorectal cancer (crc) and non-small cell lung cancer (nsclc) survivors. secondary objectives: i. development of the infrastructure and strategy for a larger comparative intervention study. outline: patients undergo survivorship care planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.

Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of stage i, ii, or iii crc or nsclc * able to read and understand english * able to read and/or understand the study protocol requirements, and provide written informed consent * diagnosis of crc or nsclc * within three months of completing primary treatment (surgery, chemotherapy, radiation, or chemoradiation) * without recurrent or new primary cancers
tedizolid suppressive antimicrobial therapy in a reference center

Conditions: Bone and Joint Infection

Summary: the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.


Eligibility criteria:
inclusion criteria: * patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy exclusion criteria: -

Keywords: bone and joint infection tedizolid suppressive antibiotic therapy
ledipasvir/sofosbuvir fixed-dose combination for 12 or 24 weeks in genotype 1 or 4 hcv infected adults with sickle cell disease

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) administered for 12 or 24 weeks in adults with genotype 1 or 4 hepatitis c virus (hcv) infection with sickle cell disease (scd).


Eligibility criteria:
key inclusion criteria: * chronic genotype 1 or 4 infected patients with sickle cell disease * hcv rna ≥ 1,000 iu/ml at screening * cirrhosis determination by transient elastography * screening laboratory values within defined thresholds * use of two effective contraception methods if female of childbearing potential or sexually active male key exclusion criteria: * pregnant or nursing female * co-infection with hiv or hepatitis b virus (hbv) * current or prior history of clinical hepatic decompensation * hepatocellular carcinoma (hcc) or other malignancy (with exception of certain resolved skin cancers) * history of clinically significant illness or any other medical disorder that may interfere with treatment, assessment or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: sickle cell disease gilead hepatitis c
ipratropium bromide spray as treatment for sialorrhea in children

Conditions: Sialorrhea

Summary: double-blind, clinical trial investigating the effects of ipratropium spray versus placebo spray in children with sialorrhea

excess drooling, or sialorrhea, is a chronic problem seen in pediatric patients with oral-motor dysfunction or neurodevelopmental abnormalities. despite significant social and physical detriment from sialorrhea, an effective and safe treatment remains elusive. the investigator's objective is to study the effect of sublingual ipratropium (an anticholinergic aerosol spray) on sialorrhea in the pediatric population method: a double-blind, randomized, placebo-controlled cross-over trial of sublingual ipratropium bromide application in pediatric patients with inappropriate drooling. patients are recruited from the sialorrhea clinic and informed consent is obtained. patients are randomized to receive ipratropium bromide, 1- 2 metered doses (sprays) of active drug (21 micrograms per metered dose) or matching placebo, every 6 hours up to a maximum of 4 times per day, in a double-blind, cross-over design using randomization tables. total treatment length is two weeks for each limb of the study with a 2 week washout period. the primary outcome measure is the reporting of sialorrhea using a validated scales. secondary outcome includes global assessment of treatment, patient satisfaction, and adverse effects.

Eligibility criteria:
inclusion criteria: * children and adolescents aged 5-18 with a history of excessive drooling exclusion criteria: * known hypersensitivity to ipratropium bromide * surgery for sialorrhea within one year * the concurrent use of acetylcholinesterase inhibitors, cholinergic agents, or anticholinergic agents * botulinum toxin for drooling within the preceding six months * a history of glaucoma * the presence of clinically significant urinary retention or outflow obstruction as evidenced by patient history or documented urodynamic studies

Keywords: ipratropium bromide sialorrhea pediatric
a study to assess treatment patterns, clinical outcomes, and healthcare resource utilization in chinese participants receiving upadacitinib for atopic dermatitis (ad) through chart review

Conditions: Atopic Dermatitis (AD)

Summary: atopic dermatitis (ad) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions. this study will assess treatment patterns, treatment outcomes, healthcare resource utilization in chinese participants receiving upadacitinib for atopic dermatitis (ad) undergoing chart review.


Eligibility criteria:
inclusion criteria: * participants with at least one primary diagnosis of atopic dermatitis with icd-10 code of l20.900 \[atopic dermatitis, unspecified\] or physician-confirmed atopic dermatitis documentation within the study period * participants with at least one documented health record of upadacitinib prescription that has a primary diagnosis of atopic dermatitis within the study period * participants with at least one atopic dermatitis severity measures (i.e., easi) in the follow-up period including up to 6 months after the index date exclusion criteria: • participants who did not fulfill the inclusion criteria will be excluded

Keywords: atopic dermatitis (ad) upadacitinib